File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Management of recurrent hepatocellular carcinoma after liver transplant – a single center experience

TitleManagement of recurrent hepatocellular carcinoma after liver transplant – a single center experience
Authors
KeywordsHepatocellular carcinoma
Recurrence
Liver resection
Transarterial chemoembolization
Liver transplantation
Issue Date2014
PublisherAustin Publishing Group. The Journal's web site is located at http://austinpublishinggroup.com/hepatitis/
The Athens Institute for Education and Research. The conference web site is located at http://www.atiner.gr/architecture.htm
Citation
Journal of Hepatitis Research, 2014, v. 1 n. 3, article no. 1014 How to Cite?
AbstractBackground: Hepatocellular carcinoma (HCC) recurs in 10-60% of patients after liver transplantation and carries very dismal prognosis. Optimal management of this condition has yet to be defined. Patients and Methods: All adult patients with HCC within the UCSF (University of California, San Francisco) criteria who underwent liver transplantation at Queen Mary Hospital during the period from July 1995 to September 2013 were reviewed. Two hundred and fifty-two patients were included in the analysis. They were divided into three groups for comparison: with intrahepatic recurrence (IR), with multiple or extrahepatic recurrence (MR), with no recurrence (NR). Results: HCC recurrence occurred in 35 (13.9%) patients, 3 with IR and 32 with MR. Patients in the IR and MR groups had a younger age (51 vs. 51 vs. 56 years; p=0.007), a higher pretransplant serum α-fetoprotein level (27 vs. 97.5 vs. 18 ng/mL; p=0.005), more tumor nodules (4 vs. 2 vs. 1; p=0.003) and a higher incidence of lymphovascular permeation (33% vs. 59% vs. 27%; p=0.001) than patients in the NR group. More patients in the IR and MR groups had tumors beyond the UCSF criteria on histopathology (67% vs. 56% vs. 17%) when compared with the NR group. Treatments for IR included hepatectomy, radiofrequency ablation and transarterial chemoembolization. One patient with IR remained alive 3 years after last treatment. Overall survival in the IR group was longer than that in the MR group (59 vs. 30.4 months; p<0.001). Time from transplant to recurrence was similar between the two groups (23.1 vs. 12 months; p=0.141). Conclusions: Recurrence of HCC after liver transplantation is not uncommon. Aggressive surgical treatment may prolong survival in patients with IR only. Prognosis for patients with MR is dismal. Effective systemic therapy is urgently needed.
Persistent Identifierhttp://hdl.handle.net/10722/207721
ISSN

 

DC FieldValueLanguage
dc.contributor.authorChok, KSH-
dc.contributor.authorFung, JYY-
dc.contributor.authorCheung, TT-
dc.contributor.authorChan, ACY-
dc.contributor.authorSharr, WW-
dc.contributor.authorChan, SC-
dc.contributor.authorLo, CM-
dc.date.accessioned2015-01-19T09:27:31Z-
dc.date.available2015-01-19T09:27:31Z-
dc.date.issued2014-
dc.identifier.citationJournal of Hepatitis Research, 2014, v. 1 n. 3, article no. 1014-
dc.identifier.issn2381-9057-
dc.identifier.urihttp://hdl.handle.net/10722/207721-
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) recurs in 10-60% of patients after liver transplantation and carries very dismal prognosis. Optimal management of this condition has yet to be defined. Patients and Methods: All adult patients with HCC within the UCSF (University of California, San Francisco) criteria who underwent liver transplantation at Queen Mary Hospital during the period from July 1995 to September 2013 were reviewed. Two hundred and fifty-two patients were included in the analysis. They were divided into three groups for comparison: with intrahepatic recurrence (IR), with multiple or extrahepatic recurrence (MR), with no recurrence (NR). Results: HCC recurrence occurred in 35 (13.9%) patients, 3 with IR and 32 with MR. Patients in the IR and MR groups had a younger age (51 vs. 51 vs. 56 years; p=0.007), a higher pretransplant serum α-fetoprotein level (27 vs. 97.5 vs. 18 ng/mL; p=0.005), more tumor nodules (4 vs. 2 vs. 1; p=0.003) and a higher incidence of lymphovascular permeation (33% vs. 59% vs. 27%; p=0.001) than patients in the NR group. More patients in the IR and MR groups had tumors beyond the UCSF criteria on histopathology (67% vs. 56% vs. 17%) when compared with the NR group. Treatments for IR included hepatectomy, radiofrequency ablation and transarterial chemoembolization. One patient with IR remained alive 3 years after last treatment. Overall survival in the IR group was longer than that in the MR group (59 vs. 30.4 months; p<0.001). Time from transplant to recurrence was similar between the two groups (23.1 vs. 12 months; p=0.141). Conclusions: Recurrence of HCC after liver transplantation is not uncommon. Aggressive surgical treatment may prolong survival in patients with IR only. Prognosis for patients with MR is dismal. Effective systemic therapy is urgently needed.-
dc.languageeng-
dc.publisherAustin Publishing Group. The Journal's web site is located at http://austinpublishinggroup.com/hepatitis/-
dc.publisherThe Athens Institute for Education and Research. The conference web site is located at http://www.atiner.gr/architecture.htm-
dc.relation.ispartofJournal of Hepatitis Research-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectHepatocellular carcinoma-
dc.subjectRecurrence-
dc.subjectLiver resection-
dc.subjectTransarterial chemoembolization-
dc.subjectLiver transplantation-
dc.titleManagement of recurrent hepatocellular carcinoma after liver transplant – a single center experience-
dc.typeArticle-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailSharr, WW: wwsharr@hku.hk-
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.authorityFung, JYY=rp00518en_US
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.description.naturepublished_or_final_version-
dc.identifier.hkuros242004-
dc.identifier.volume1-
dc.identifier.issue3-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats